Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals    VRTX

VERTEX PHARMACEUTICALS

(VRTX)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/16/2019 07/17/2019 07/18/2019 07/19/2019 07/22/2019 Date
176.16(c) 177.14(c) 178.09(c) 174.13(c) 174.08 Last
619 960 773 112 853 492 1 121 646 1 120 958 Volume
-0.12% +0.56% +0.54% -2.22% -0.03% Change
More quotes
Financials (USD)
Sales 2019 3 559 M
EBIT 2019 1 441 M
Net income 2019 849 M
Finance 2019 3 499 M
Yield 2019 -
Sales 2020 4 405 M
EBIT 2020 2 111 M
Net income 2020 1 264 M
Finance 2020 5 350 M
Yield 2020 -
P/E ratio 2019 53,9x
P/E ratio 2020 36,3x
EV / Sales2019 11,5x
EV / Sales2020 8,91x
Capitalization 44 586 M
More Financials
Company
Vertex Pharmaceuticals specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales break down by type of income as follows: - income from sales of products (99.7%); - royalties and... 
More about the company
Surperformance© ratings of Vertex Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on VERTEX PHARMACEUTICALS
08:04aVERTEX PHARMACEUTICALS : Submits New Drug Application to the U.S. FDA for Triple..
BU
07/17VERTEX PHARMACEUTICALS : to Announce Second-Quarter 2019 Financial Results on Ju..
BU
06/24VERTEX PHARMACEUTICALS : FDA Approves SYMDEKO to Treat the Underlying Cause of C..
AQ
06/21VERTEX PHARMACEUTICALS : FDA Approves SYMDEKO® (tezacaftor/ivacaftor and ivacaft..
BU
06/21SPERO THERAPEUTICS : Announces Collaboration with Bill & Melinda Gates Medica..
AQ
06/13GSK signs up gene-editing pioneers in drug discovery alliance
RE
06/07VERTEX PHARMACEUTICALS INC / MA : Entry into a Material Definitive Agreement (fo..
AQ
06/05VERTEX PHARMACEUTICALS INC / MA : Change in Directors or Principal Officers, Sub..
AQ
06/04VERTEX PHARMACEUTICALS : to Present Data at ECFS Conference on Potential Impact ..
BU
05/30VERTEX PHARMACEUTICALS : Selects Triple Combination Regimen of VX-445, Tezacafto..
BU
More news
Analyst Recommendations on VERTEX PHARMACEUTICALS
More recommendations
Sector news : Bio Therapeutic Drugs
11:37aGILEAD SCIENCES : Says Study of GS-6207 Showed HIV Capsid Inhibition Can Lead Vi..
DJ
08:54aGILEAD SCIENCES : Licenses Durect's Saber Technology for Injectable HIV Product
DJ
07/19Gilead Licenses Respiratory, Herpes Antiviral Research Programs From Novartis
DJ
07/17GILEAD SCIENCES : Chief Scientific Officer John McHutchison to Leave
DJ
07/16As steep patent cliff looms, Shionogi moves to develop its own U.S. sales sta..
RE
More sector news : Bio Therapeutic Drugs
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 209,10  $
Last Close Price 174,08  $
Spread / Highest target 34,4%
Spread / Average Target 20,1%
Spread / Lowest Target -0,05%
EPS Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Paul M. Silva Chief Financial Officer, Controller & Senior VP
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Reshma Kewalramani Chief Medical Officer & Executive Vice President
Bruce I. Sachs Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS5.08%44 598
GILEAD SCIENCES3.98%82 702
REGENERON PHARMACEUTICALS-20.18%32 544
GENMAB14.24%11 908
SAREPTA THERAPEUTICS INC36.77%11 068
ARRAY BIOPHARMA INC226.25%10 372